Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF CANCER AND OTHER TARGET DISEASES
5.1.2 GROWING AWARENESS AND ACCEPTANCE OF CAR-T CELL THERAPY
5.1.3 SUPPORTIVE GOVERNMENT INITIATIVES AND FUNDING FOR HEALTHCARE INNOVATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF CAR-T CELL THERAPY
5.2.2 REGULATORY HURDLES RESULT THE DELAY IN CAR T-CELL THERAPY APPROVAL
5.3 OPPORTUNITIES
5.3.1 THE EXTENSIVE PIPELINE OF CAR-T CELL THERAPY
5.3.2 THE DEVELOPMENT OF NOVEL THERAPIES AND COMBINATION TREATMENTS
5.4 CHALLENGES
5.4.1 POTENTIAL RISKS AND ADVERSE EFFECTS OF TREATMENT
5.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS AND THERAPIES
6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENTN MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 AUTOLOGOUS CAR-T CELLS
6.3 ALLOGENEIC CAR-T CELLS
7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY STRUCTURE
7.1 OVERVIEW
7.2 SECOND GENERATION CAR-T CELLS
7.3 THIRD GENERATION CAR-T CELLS
7.4 FOURTH GENERATION CAR-T CELLS
7.5 FIRST GENERATION CAR-T CELLS
8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
8.1 OVERVIEW
8.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
8.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
8.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
8.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
8.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
8.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
8.3 ANTIGENS ON SOLID TUMORS
8.4 OTHERS
9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY BRAND
9.1 OVERVIEW
9.2 KYMRIAH
9.3 YESCARTA
9.4 TECARTUS
9.5 OTHERS
10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY THERAPEUTICS APPLICATION
10.1 OVERVIEW
10.2 DIFFUSE LARGE B-CELL LYMPHOMA
10.3 FOLLICULAR LYMPHOMA
10.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
10.5 MANTLE CELL LYMPHOMA
10.6 MULTIPLE MYELOMA
10.7 LUNG CANCER
10.8 CHRONIC LYMPHOCYTIC LEUKEMIA
10.9 GASTRIC CANCER
10.1 PANCREATIC CANCER
10.11 BREAST CANCER
10.12 OTHERS
11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 OTHERS
12 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY, DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 OTHERS
13 MEA, SAUDI ARABIA, SEA CAR-T CELL THERAPY MARKET, BY COUNTRY
13.1 MEA
13.1.1 SAUDI ARABIA
13.1.2 U.A.E.
13.1.3 SOUTH AFRICA
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
13.2 SEA
13.2.1 SINGAPORE
13.2.2 MALAYSIA
13.2.3 THAILAND
13.2.4 INDONESIA
13.2.5 PHILIPPINES
13.2.6 VIETNAM
14 MEA AND SEA CAR-T CELL THERAPY MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MEA
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 NOVARTIS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 GILEAD SCIENCES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 BRISTOL-MYERS SQUIBB COMPANY
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 JOHNSON & JOHNSON SERVICES, INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA)
TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET
FIGURE 14 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 15 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 16 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 17 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 18 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2027-2031)
FIGURE 19 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 21 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2024-2031)
FIGURE 22 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 23 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 24 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2027-2031)
FIGURE 25 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 27 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, CAGR (2024-2031)
FIGURE 28 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 29 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 30 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, CAGR (2027-2031)
FIGURE 31 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 32 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 33 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2024-2031)
FIGURE 34 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 35 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 36 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, CAGR (2027-2031)
FIGURE 37 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, LIFELINE CURVE
FIGURE 38 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 39 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, CAGR (2024-2031)
FIGURE 40 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 41 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 42 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, CAGR (2027-2031)
FIGURE 43 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 44 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 45 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 48 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2027-2031)
FIGURE 49 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 50 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 51 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 52 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 54 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2027-2031)
FIGURE 55 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 MEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 57 SEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 58 MEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 59 SEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
